NASDAQ · INAB
Healthcare · Biotechnology
$1.10
Up+$0.02 (+1.85%)
Updated Sep 11, 2026, 7:00 AM
SID Score
3.1/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
INAB closed at $1.10 after 20 trading sessions, down 6.78% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 10, 2026 | $1.08 | $1.11 | $1.08 | $1.10 | 15.63K |
| Sep 9, 2026 | $1.10 | $1.125 | $1.08 | $1.08 | 21.47K |
| Sep 8, 2026 | $1.20 | $1.20 | $1.13 | $1.14 | 31.42K |
| Sep 4, 2026 | $1.16 | $1.22 | $1.16 | $1.20 | 22.39K |
| Sep 3, 2026 | $1.10 | $1.16 | $1.0962 | $1.16 | 41.54K |
| Sep 2, 2026 | $1.09 | $1.11 | $1.085 | $1.10 | 6.74K |
| Sep 1, 2026 | $1.10 | $1.13 | $1.08 | $1.09 | 19.95K |
| Aug 31, 2026 | $1.01 | $1.13 | $1.01 | $1.10 | 36.92K |
| Aug 28, 2026 | $1.04 | $1.05 | $1.03 | $1.035 | 24.33K |
| Aug 27, 2026 | $1.19 | $1.19 | $0.96 | $1.04 | 130.38K |
| Aug 26, 2026 | $1.17 | $1.20 | $1.165 | $1.185 | 3.35K |
| Aug 25, 2026 | $1.18 | $1.2001 | $1.11 | $1.17 | 58.73K |
| Aug 24, 2026 | $1.30 | $1.30 | $1.145 | $1.18 | 72.79K |
| Aug 21, 2026 | $1.23 | $1.30 | $1.18 | $1.28 | 105.89K |
| Aug 20, 2026 | $1.22 | $1.2547 | $1.17 | $1.21 | 17.25K |
| Aug 19, 2026 | $1.16 | $1.26 | $1.155 | $1.20 | 79.1K |
| Aug 18, 2026 | $1.135 | $1.17 | $1.13 | $1.14 | 45.28K |
| Aug 17, 2026 | $1.11 | $1.14 | $1.052 | $1.11 | 36.96K |
| Aug 14, 2026 | $1.19 | $1.1998 | $1.10 | $1.10 | 56.01K |
| Aug 13, 2026 | $0.9994 | $1.19 | $0.94 | $1.18 | 375.67K |
The latest Smart Investors Daily articles mentioning INAB.
INAB research
Company profile and research snapshot.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Mar 13, 2026 | HC Wainwright & Co. | Buy | — |
| Mar 14, 2025 | HC Wainwright & Co. | Buy | — |
| Feb 12, 2025 | HC Wainwright & Co. | Buy | — |
| Feb 11, 2025 | Jones Trading | Buy | — |
| Nov 26, 2024 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Benzinga · Aug 6, 2026
IN8bio (NASDAQ:INAB) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.37) by 32.43 percent. This is a 79.84 percent increase over losses of $(1.24) per share from the same
Benzinga · Jul 9, 2026
First peer-reviewed publication of chemotherapy-resistant gamma-delta T cells (DeltEx Drug Resistant Immunotherapy or DRI) clinical results in newly diagnosed glioblastoma Repeat-dose patients achieved median
Benzinga · Mar 13, 2026
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates IN8bio (NASDAQ:INAB) with a Buy and maintains $6 price target.
Benzinga · Mar 12, 2026
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning INAB.
